New agreement supersedes the collaboration agreement entered in 2012
GSK retains non-exceptional appropriate to use PRINT for pre-scientific analysis for inhaled delivery
Liquidia can implement PRINT to any inhaled software other than recognized GSK proprietary molecules
MORRISVILLE, N.C., April 03, 2023 (World NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Business) introduced nowadays that it has entered a new, non-distinctive license arrangement with GSK to empower pre-clinical investigation of inhaled formulations of GSK’s molecules based mostly upon Liquidia’s proprietary PRINT® technology. This agreement supersedes the collaboration arrangement amongst the events from 2012. Liquidia now will have the suitable to apply PRINT to all inhaled formulations other than certain identified GSK proprietary molecules. GSK will keep a non-unique, non-sublicensable, royalty-absolutely free license for the sole reason of conducting pre-medical research and pre-medical progress.
Roger Jeffs, Main Government Officer of Liquidia, said: “We are really delighted to have re-structured our relationship with GSK to enable both functions to optimize the established gains of PRINT technologies for inhaled shipping and delivery. As demonstrated by YUTREPIA™, the ability to exactly engineer uniform particles for inhalation can greatly enhance patient gains. This settlement will permit Liquidia to produce extra goods and